Legal Settlements and Loss Contingencies	12 Months Ended
Dec. 31, 2019
Legal Settlements and Loss Contingencies	NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies for 2019 amounted to an expense of $1,178 million, compared to an inc ome of $1,208 million and an expense of $500 million in 2018 and 2017, respectively. The expense in 2019 w as mainly related to an estimated provision recorded in connection with settlement of the remaining opioid cases. The 2018 income primarily consisted of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation. As of December 31, 2019 and 2018, accrued amounts for legal settlements and loss contingencies of $1,580 million and $562 million, respectively, we re recorded in accrued expenses.

Legal Settlements and Loss Contingencies

12 Months Ended

Dec. 31, 2019

Legal Settlements and Loss Contingencies

NOTE 11—Legal settlements and loss contingencies:

Legal settlements and loss contingencies for 2019 amounted to an

expense

of $1,178 million, compared to

an inc

ome

of $1,208

million and an expense of $500 million in 2018 and 2017, respectively. The expense in 2019 w

mainly related to an estimated provision recorded in connection with

settlement of

the remaining opioid cases. The 2018 income primarily consisted of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation.

As of December 31, 2019 and 2018, accrued amounts for legal settlements and loss contingencies of $1,580 million and $562 million, respectively,

re recorded in accrued expenses.